Drugs Xagena
Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody Romosozumab binds to sclerostin and increases bone formation.
In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, researchers have evaluated the efficacy and safety of Romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density ( a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites ).
Participants were randomly assigned to receive subcutaneous Romosozumab monthly ( at a dose of 70 mg, 140 mg, or 210 mg ) or every 3 months ( 140 mg or 210 mg ), subcutaneous placebo, or an open-label active comparator, oral Alendronate ( 70 mg weekly ) or subcutaneous Teriparatide ( 20 mcg daily ).
The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover.
All dose levels of Romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with Alendronate and 7.1% with Teriparatide.
Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker.
Except for mild, generally nonrecurring injection-site reactions with Romosozumab, adverse events were similar among groups.
The study has shown that, in postmenopausal women with low bone mass, Romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. ( Xagena )
McClung MR et al, N Engl J Med 2014; 370: 412-420
XagenaMedicine_2014
